Next generation biologics, such as extracellular vesicle-based therapeutics, will eliminate the current shortcomings of stem cell therapies regarding personalization, dosing, and unexpected side effects. Small New World Laboratories develops and manufactures human cell-derived advanced biologics to improve and accelerate the body´s endogenous healing process by suppressing inflammatory immunoreactivity and fibrosis and engages in contract process development and contract manufacturing activities to support basic researchers and economically oriented companies in reaching their individual goals.
Small New World Laboratories participates in FACTORY+ #8 (AplusB program) in 2023/24.